Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Delayed London Stock Exchange  -  11:35 2022-12-02 am EST
1424.00 GBX   +0.61%
12/02ADRs End Mostly Higher, H World and RedHill BioPharma Trade Actively
DJ
12/02Plunging Eurozone Industrial Producer Prices Push European Equities Lower
MT
12/02Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Haleon rejects Zantac indemnification requests from GSK, Pfizer

09/20/2022 | 02:17am EST
The company logo for Haleon and the trading info is displayed on a screen on the floor of the NYSE in New York

LONDON (Reuters) - Haleon on Tuesday said it had notified GSK and Pfizer that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac.

More than 2,000 legal cases related to Zantac have been filed in the United States over allegations that the compound contains probable carcinogens.

Zantac, originally marketed by a forerunner of GSK, has been sold by several companies at different times, including Pfizer, Boehringer Ingelheim and Sanofi as well as a plethora of generic drugmakers.

Haleon, spun out as an independent company in July, comprises consumer health assets once owned by GSK and Pfizer.

(Reporting by Natalie Grover in London; Editing by Louise Heavens)


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
GSK PLC 0.61% 1424 Delayed Quote.-13.36%
HALEON PLC -0.51% 291.45 Delayed Quote.0.00%
PFIZER, INC. -0.33% 50.91 Delayed Quote.-13.50%
SANOFI -1.92% 85.77 Real-time Quote.-3.17%
All news about GSK PLC
12/02ADRs End Mostly Higher, H World and RedHill BioPharma Trade Actively
DJ
12/02Plunging Eurozone Industrial Producer Prices Push European Equities Lower
MT
12/02Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned inter..
AQ
12/02AnaptysBio: Trial of Jemperli Drug Meets Primary Endpoint
DJ
12/02Is the job report good or bad news?
MS
12/02GSK Says Cancer Drug Met Primary Endpoint in Interim Analysis of Phase 3 Trial
MT
12/02GSK Says European Medicines Agency Accepted Marketing Authorization Application for Pot..
MT
12/02Gsk : European Medicines Agency accepts marketing authorisation application for momelotini..
PU
12/02Analyst recommendations: Blackstone, BT Group, Ecolab, GSK, Sain..
MS
12/02Citigroup Cuts GSK PT, Keeps Neutral Rating
MT
More news
Analyst Recommendations on GSK PLC
More recommendations
Financials
Sales 2022 29 178 M 35 741 M 35 741 M
Net income 2022 4 322 M 5 294 M 5 294 M
Net Debt 2022 14 343 M 17 570 M 17 570 M
P/E ratio 2022 12,7x
Yield 2022 4,23%
Capitalization 57 447 M 70 368 M 70 368 M
EV / Sales 2022 2,46x
EV / Sales 2023 2,36x
Nbr of Employees 90 096
Free-Float 93,7%
Chart GSK PLC
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 1 424,00 GBX
Average target price 1 709,73 GBX
Spread / Average Target 20,1%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC-13.36%70 368
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY34.07%356 089
ABBVIE INC.20.87%289 331
NOVO NORDISK A/S22.04%285 887
PFIZER, INC.-13.50%285 774